Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a
biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ( UCRI ) to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP). Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research. We are pleased to commence a new research program with Dr. Hassett and the University of Cincinnati Research Institute, said Robb Knie, CEO of Hoth Therapeutics. There is a growing need for new antibiotic therapies targete
(HOTH) - Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.